drugset / Trial / NCT00239395

A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis

NCT00239395

Phase 3 Completed 168 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this trial was to assess the efficacy and safety of 7.5 mg meloxicam i.m. once daily compared with 7.5 mg meloxicam tablets once daily p.o. in patients with osteoarthritis over a time period of 7 days.

Timeline

Start
2004-07
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 7.5 mg Intramuscular

Indications